VA SAN diego pharmacy service is requesting a sole source procurement from alliancerx walgreens specialty pharmacy, a sole distributor for tolvaptan (JYNARQUE)
Ended Awarded Last action
- Contract number
- 36C26223F0027
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $132,074
Award facts
- Contract value 100% obligated
- $132,073.87 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$5,034 | |
| Original award | $137,108 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 22 (VISN 22) in San Diego awarded a delivery order to Otsuka America Pharmaceutical Inc. valued at $132,073.87 on October 13, 2022, for the sole-source procurement of Jynarque (tolvaptan) through AllianceRx Walgreens Specialty Pharmacy, the sole authorized distributor. The contract is firm-fixed price with no set-aside designation and was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Performance is based in Pittsburgh, Pennsylvania, with an ultimate completion date of September 30, 2023. This delivery order represents a task order against Otsuka America Pharmaceutical Inc.'s larger Blanket Purchase Agreement with the VA's National Acquisition Center, valued at approximately $83.3 million and extending through March 26, 2026.
Jynarque is a specialized pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veterans. The sole-source justification reflects the medication's unique therapeutic profile and Otsuka America Pharmaceutical Inc.'s exclusive manufacturing and distribution rights. This procurement aligns with the VA's mission to provide comprehensive, specialized healthcare services to veterans, enabling VISN 22 facilities to access critical pharmaceutical treatments through streamlined delivery order mechanisms. The firm maintains a robust federal contracting relationship with the VA across multiple integrated service networks, with delivery orders for Jynarque typically ranging from $10,000 to $113,000 in value.
Quick answers
Who was awarded contract 36C26223F0027?
36C26223F0027 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on October 13, 2022.
How much is contract 36C26223F0027 worth?
The government has obligated $132,074 on 36C26223F0027.
Is contract 36C26223F0027 an order under another contract?
Yes. 36C26223F0027 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26223F0027 competed?
The extent of competition for 36C26223F0027 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award